Rationale: Crescent formation is rare in primary membranous nephropathy (MN). Anti-phospholipase A2 receptor (PLA2R) antibodies are detectable in these patients. The mechanism and treatments are unknown.
Patient Concerns: A 72-year-old female patient who presented with nephrotic syndrome, hematuria, and rapidly progressive kidney dysfunction.
Diagnoses: Kidney biopsy was performed and the diagnosis was MN in combination with crescentic glomerulonephritis. Circulating anti-PLA2R IgG3 and IgG4 were detected of high level.
Interventions: The patient received plasma exchange and rituximab besides corticosteroids.
Outcomes: The patient achieved complete remission of proteinuria and recovery of kidney function after the clearance of anti-PLA2R antibodies.
Lesson: This case suggests a pathogenic role of anti-PLA2R antibodies in the mechanism of crescent formation in MN, which may need intensive therapy to eliminate the antibodies quickly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504248 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000015303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Post-COVID cognitive dysfunctions, impacting attention, memory, and learning, might be linked to inflammation-induced blood-brain barrier (BBB) impairment. This study explores post-COVID BBB permeability changes using a non-contrast water-exchange based MRI and their associations with blood Alzheimer's biomarkers.
Method: Sixty-seven participants were classified based on COVID (COV) and cognitive (COG) statuses into three groups: COV+/COG- (n=34), COV+/COG+ (n=23), and COV- (n=10) for comparisons (COV+: Laboratory-verified SARS-CoV-2 infection; COV-: No history of SARS-CoV-2 infection and negative SARS-CoV-2 nucleocapsid antibody test.
Background: Non-invasive biofluid and MRI measures of blood-brain-barrier (BBB) dysfunction may aid early detection of cerebral small vessel disease (cSVD). Plasma markers of astrocytic function and injury, such as S100 calcium-binding protein B (S100b), have gained increased attention in relation to BBB integrity and cognition. Here we explored the inter-relationships between plasma S100b levels, an MRI measure of water exchange rate across the BBB (kw), and cognitive performance among older adults.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Biorepositories play an integral role in the advancement of our understanding of neurodegenerative diseases and improving human health outcomes. Research efforts are accelerated when access to high-quality clinical specimens is made available from a large, diverse participant group. Indiana University is home to three important neurodegenerative disease-focused biorepositories including the NIA-funded National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), the NINDS-funded Biospecimen Exchange for Neurological Disorders (BioSEND), and the Michael J.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
National Institute of Neurological Disorders and Stroke, Rockville, MD, USA.
Background: Access to biospecimens is an oft cited challenge to the progress in research on neurological disorders. Access to clinical biospecimens for development of validated biomarkers and improved cellular models of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) are cited as priorities across several NIH AD/ADRD Research Implementation Milestones (https://www.nia.
View Article and Find Full Text PDFBackground: Blood exchange experiments in heterochronic parabionts or heterochronic plasma transfer have revealed that age-associated changes in blood composition contribute to neurogenesis and cognitive impairment in the elderly, and multiple blood-born pro-aging factors have been identified as causal factors to accelerate age-dependent brain changes. We previously demonstrate that PDGF-BB secreted by pre-osteoclasts in bone mediates cerebrovascular impairment during aging, but the bone-derived PDGF-BB in Alzheimer's disease (AD) progression is still uncertain.
Methods: MCI patients and two transgenic AD mouse models, App-ps1 and 5XFAD, were used to evaluated PDGF-BB level by ELISA measurement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!